Open Access Articles- Top Results for Edivoxetine


File:Edivoxetine structure.png
Systematic (IUPAC) name
Clinical data
1194374-05-4 (hydrochloride)
PubChem CID 11186829
ChemSpider 9361913
Chemical data
Formula C18H26FNO4
339.402 g/mol

Edivoxetine (INN; LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment.[1][2] It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.[1][3]


In a study published in 2010, edivoxetine failed to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]

In a study published in 2011, using the Montgomery-Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]

In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]

Side effects

Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.[4]

The above mention studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.[4][5]

See also


  1. ^ a b Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News (American Psychiatric Association) 47 (5): 1b-29. Retrieved 2012-04-27. 
  2. ^ "Statement on a nonproprietary name adopted by the USAN council - Edivoxetine" (PDF) (Press release). American Medical Association. 2012. Retrieved 2012-04-12. 
  3. ^ Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery 10 (11): 809–10. PMID 22037032. doi:10.1038/nrd3585. 
  4. ^ a b c Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression". Journal of Psychiatric Research 44 (6): 356–363. PMID 19909980. doi:10.1016/j.jpsychires.2009.09.013. 
  5. ^ a b Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder". Journal of Psychiatric Research 45 (6): 748–755. PMID 21511276. doi:10.1016/j.jpsychires.2011.03.014. 
  6. ^